{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:54:06Z","timestamp":1792601646988,"version":"4.5.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T00:00:00Z","timestamp":1478217600000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI66922"],"award-info":[{"award-number":["R01AI66922"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30AI042853"],"award-info":[{"award-number":["P30AI042853"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32DA13911\u201310"],"award-info":[{"award-number":["T32DA13911\u201310"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background. \u2003Human immunodeficiency virus (HIV)-1 drug resistance mutations (DRMs) often accompany treatment failure. Although subtype differences are widely studied, DRM comparisons between subtypes either focus on specific geographic regions or include populations with heterogeneous treatments.<\/jats:p>\n               <jats:p>Methods. \u2003We characterized DRM patterns following first-line failure and their impact on future treatment in a global, multi-subtype reverse-transcriptase sequence dataset. We developed a hierarchical modeling approach to address the high-dimensional challenge of modeling and comparing frequencies of multiple DRMs in varying first-line regimens, durations, and subtypes. Drug resistance mutation co-occurrence was characterized using a novel application of a statistical network model.<\/jats:p>\n               <jats:p>Results. \u2003In 1425 sequences, 202 subtype B, 696 C, 44 G, 351 circulating recombinant forms (CRF)01_AE, 58 CRF02_AG, and 74 from other subtypes mutation frequencies were higher in subtypes C and CRF01_AE compared with B overall. Mutation frequency increased by 9%\u201320% at reverse transcriptase positions 41, 67, 70, 184, 215, and 219 in subtype C and CRF01_AE vs B. Subtype C and CRF01_AE exhibited higher predicted cross-resistance (+12%\u201318%) to future therapy options compared with subtype B. Topologies of subtype mutation networks were mostly similar.<\/jats:p>\n               <jats:p>Conclusions. \u2003We find clear differences in DRM outcomes following first-line failure, suggesting subtype-specific ecological or biological factors that determine DRM patterns.<\/jats:p>","DOI":"10.1093\/ofid\/ofv158","type":"journal-article","created":{"date-parts":[[2015,11,4]],"date-time":"2015-11-04T03:45:05Z","timestamp":1446608705000},"source":"Crossref","is-referenced-by-count":21,"title":["Global Comparison of Drug Resistance Mutations After First-Line Antiretroviral Therapy Across Human Immunodeficiency Virus-1 Subtypes"],"prefix":"10.1093","volume":"3","author":[{"given":"Austin","family":"Huang","sequence":"first","affiliation":[{"name":"Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph W.","family":"Hogan","sequence":"additional","affiliation":[{"name":"Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Luo","sequence":"additional","affiliation":[{"name":"Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"DeLong","sequence":"additional","affiliation":[{"name":"Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanmugam","family":"Saravanan","sequence":"additional","affiliation":[{"name":"YRG CARE, Chennai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasong","family":"Wu","sequence":"additional","affiliation":[{"name":"National Centre for AIDS\/STD Control and Prevention, Chinese Centre for Disease Control and Prevention, Beijing Ditan Hospital, Capital Medical University, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunee","family":"Sirivichayakul","sequence":"additional","affiliation":[{"name":"Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagalingeswaran","family":"Kumarasamy","sequence":"additional","affiliation":[{"name":"YRG CARE, Chennai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujie","family":"Zhang","sequence":"additional","affiliation":[{"name":"National Centre for AIDS\/STD Control and Prevention, Chinese Centre for Disease Control and Prevention, Beijing Ditan Hospital, Capital Medical University, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praphan","family":"Phanuphak","sequence":"additional","affiliation":[{"name":"Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lameck","family":"Diero","sequence":"additional","affiliation":[{"name":"Moi University, Eldoret, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Buziba","sequence":"additional","affiliation":[{"name":"Moi University, Eldoret, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorin","family":"Istrail","sequence":"additional","affiliation":[{"name":"Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Katzenstein","sequence":"additional","affiliation":[{"name":"Stanford University, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Kantor","sequence":"additional","affiliation":[{"name":"Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,11,3]]},"reference":[{"key":"2020081005364400800_OFV158C1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"2020081005364400800_OFV158C2","article-title":"Consolidated guidelines on general HIV care and the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach.","author":"World Health Organization"},{"key":"2020081005364400800_OFV158C3","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1056\/NEJMra1201533","article-title":"Response to the AIDS pandemic\u2014a global health model","volume":"368","author":"Piot","year":"2013","journal-title":"N Engl J Med"},{"key":"2020081005364400800_OFV158C4","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1056\/NEJMra0706737","article-title":"The challenge of HIV-1 subtype diversity","volume":"358","author":"Taylor","year":"2008","journal-title":"N Engl J Med"},{"key":"2020081005364400800_OFV158C5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1126\/science.288.5463.55d","article-title":"HIV-1 nomenclature proposal","volume":"288","author":"Robertson","year":"2000","journal-title":"Science"},{"key":"2020081005364400800_OFV158C6","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/QAD.0b013e328342ff93","article-title":"Global trends in molecular epidemiology of HIV-1 during 2000\u20132007","volume":"25","author":"Hemelaar","year":"2011","journal-title":"AIDS"},{"key":"2020081005364400800_OFV158C7","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1128\/JVI.02645-08","article-title":"Replicative capacity differences of thymidine analog resistance mutations in subtype B and C human immunodeficiency virus type 1","volume":"83","author":"Armstrong","year":"2009","journal-title":"J Virol"},{"key":"2020081005364400800_OFV158C8","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1128\/AAC.01505-10","article-title":"Replicative fitness costs of nonnucleoside reverse transcriptase inhibitor drug resistance mutations on HIV subtype C","volume":"55","author":"Armstrong","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081005364400800_OFV158C9","doi-asserted-by":"crossref","first-page":"e46622","DOI":"10.1371\/journal.pone.0046622","article-title":"Differential in vitro kinetics of drug resistance mutation acquisition in HIV-1 RT of subtypes B and C","volume":"7","author":"Cunha","year":"2012","journal-title":"PLoS One"},{"key":"2020081005364400800_OFV158C10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/aid.2010.0050","article-title":"Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy","volume":"27","author":"Chaplin","year":"2011","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2020081005364400800_OFV158C11","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/QAI.0b013e3181bc478b","article-title":"Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa","volume":"53","author":"Wallis","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020081005364400800_OFV158C12","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S0140-6736(05)79316-8","article-title":"Two subtypes of HIV-1 among injection-drug users in southern China","volume":"351","author":"Yu","year":"1998","journal-title":"Lancet"},{"key":"2020081005364400800_OFV158C13","doi-asserted-by":"crossref","first-page":"e9311","DOI":"10.1371\/journal.pone.0009311","article-title":"The HIV-1 subtype C epidemic in South America is linked to the United Kingdom","volume":"5","author":"De Oliveira","year":"2010","journal-title":"PloS One"},{"key":"2020081005364400800_OFV158C14","doi-asserted-by":"crossref","first-page":"F9","DOI":"10.1097\/01.aids.0000232228.88511.0b","article-title":"HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture","volume":"20","author":"Brenner","year":"2006","journal-title":"AIDS"},{"key":"2020081005364400800_OFV158C15","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2217\/hiv.09.40","article-title":"The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications","volume":"3","author":"Brenner","year":"2009","journal-title":"HIV Ther"},{"key":"2020081005364400800_OFV158C16","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1086\/382483","article-title":"Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus type 1 subtypes may influence mutational routes to drug resistance","volume":"189","author":"Dumans","year":"2004","journal-title":"J Infect Dis"},{"key":"2020081005364400800_OFV158C17","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1371\/journal.pmed.0020112","article-title":"Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration","volume":"2","author":"Kantor","year":"2005","journal-title":"PLoS Med"},{"key":"2020081005364400800_OFV158C18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2217\/fvl.12.37","article-title":"Global analysis of sequence diversity within HIV-1 subtypes across geographic regions","volume":"7","author":"Huang","year":"2012","journal-title":"Future Virol"},{"key":"2020081005364400800_OFV158C19","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1128\/AAC.48.6.2159-2165.2004","article-title":"Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir","volume":"48","author":"Grossman","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081005364400800_OFV158C20","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1089\/aid.2011.0078","article-title":"Characterization of HIV type 1 subtype C protease gene: selection of L63P mutation in protease inhibitor-naive Indian patients","volume":"27","author":"Neogi","year":"2011","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2020081005364400800_OFV158C21","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1473-3099(09)70136-7","article-title":"Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis","volume":"9","author":"Gupta","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"2020081005364400800_OFV158C22","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1093\/cid\/cis254","article-title":"Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies","volume":"54","author":"Hamers","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020081005364400800_OFV158C23","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/QCO.0b013e3280109122","article-title":"Impact of HIV-1 pol diversity on drug resistance and its clinical implications","volume":"19","author":"Kantor","year":"2006","journal-title":"Curr Opin Infect Dis"},{"key":"2020081005364400800_OFV158C24","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1126\/science.334.6063.1628","article-title":"Breakthrough of the year. HIV Treatment as Prevention","volume":"334","author":"Cohen","year":"2011","journal-title":"Science"},{"key":"2020081005364400800_OFV158C25","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1089\/aid.2009.0107","article-title":"Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine","volume":"26","author":"Manosuthi","year":"2010","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"(Suppl 2)","key":"2020081005364400800_OFV158C26","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1093\/infdis\/jit121","article-title":"The impact of HIV drug resistance on the selection of first- and second-line ART in resource-limited settings","volume":"207","author":"Bertagnolio","year":"2013","journal-title":"J Infect Dis"},{"key":"2020081005364400800_OFV158C27","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/nar\/gkg100","article-title":"Human immunodeficiency virus reverse transcriptase and protease sequence database","volume":"31","author":"Rhee","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"2020081005364400800_OFV158C28","first-page":"894","article-title":"SQUAT (Sequence Quality Assessment Tool): a standalone computational tool for HIV sequence quality evaluation","volume":"28","author":"Kantor","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2020081005364400800_OFV158C29","volume-title":"Rapid Advice: Antiretroviral Therapy for HIV Infection in Adults and Adolescents","author":"World Health Organization","year":"2009"},{"key":"2020081005364400800_OFV158C30","first-page":"6","article-title":"Update of the drug resistance mutations in HIV-1: March 2013","volume":"21","author":"Johnson","year":"2013","journal-title":"Top Antivir Med"},{"key":"2020081005364400800_OFV158C31","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/00002030-200301030-00001","article-title":"A V106 M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors","volume":"17","author":"Brenner","year":"2003","journal-title":"AIDS"},{"key":"2020081005364400800_OFV158C32","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1089\/aid.2006.0298","article-title":"The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV\/ddI-containing HAART in southern Africa","volume":"23","author":"Novitsky","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"(Suppl 2)","key":"2020081005364400800_OFV158C33","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1093\/infdis\/jit114","article-title":"Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine","volume":"207","author":"Tang","year":"2013","journal-title":"J Infect Dis"},{"key":"2020081005364400800_OFV158C34","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1128\/JVI.02712-06","article-title":"The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions","volume":"81","author":"Cong","year":"2007","journal-title":"J Virol"},{"key":"2020081005364400800_OFV158C35","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.1128\/JVI.00859-09","article-title":"Subtype-specific differences in the human immunodeficiency virus type 1 reverse transcriptase connection subdomain of CRF01_AE are associated with higher levels of resistance to 3\u2032-azido-3\u2032-deoxythymidine","volume":"83","author":"Delviks-Frankenberry","year":"2009","journal-title":"J Virol"},{"key":"2020081005364400800_OFV158C36","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.micinf.2010.08.003","article-title":"Impact of CRF01_AE-specific polymorphic mutations G335D and A371 V in the connection subdomain of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on susceptibility to nucleoside RT inhibitors","volume":"12","author":"Tanuma","year":"2010","journal-title":"Microbes Infect"},{"key":"2020081005364400800_OFV158C37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00002030-199701000-00017","article-title":"Why do HIV-1 subtypes segregate among persons with different risk behaviors in South Africa and Thailand?","volume":"11","author":"Mastro","year":"1997","journal-title":"AIDS"},{"key":"2020081005364400800_OFV158C38","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/447655a","article-title":"Replicating genotype-phenotype associations","volume":"447","author":"Chanock","year":"2007","journal-title":"Nature"},{"key":"2020081005364400800_OFV158C39","first-page":"189","article-title":"Why we (usually) don't have to worry about multiple comparisons","volume":"5","author":"Gelman","year":"2012","journal-title":"J Res Educ Eff"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/3\/2\/ofv158\/33602570\/ofv158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/3\/2\/ofv158\/33602570\/ofv158.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T09:37:08Z","timestamp":1597052228000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofv158\/2399258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,3]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofv158","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016]]},"published":{"date-parts":[[2015,11,3]]},"article-number":"ofv158"}}